CR率为99.1%的CAR-T,使近95%患者疾病未发生进展的ADC获IND进展,涉及上海医药、映恩生物等【CDE 一周动态】

医麦客
May 08

2025 年 5 月 8 日医麦客新闻 eMedClub News根据中国国家药监局药品审评中心(CDE)官网及公开资料不完全统计,上周(4 月 28 日 - 5 月 4 日),约 18 项生物创新药 IND 获批临床默示许可/IND 申请获受理。(备注:本文仅统计双抗、ADC、CAR-T 等新分子类型生物创新药)上述新进展涉及完全缓解率为 99.1% 的双顺反子 CD19/CD22 CAR-T,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10